Characterization of the murine C3a receptor enhancer-promoter: Expression control by an activator protein 1 sequence and an Ets-like site

Journal of Immunology

Volumn 175, Issue 5, 2005, Pages 3123-3132

  Martin, Carol B ^a   Martin, Brian K ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3A RECEPTOR; COMPLEMENT COMPONENT C5A; COMPLEMENT RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR ETS 2; TRANSCRIPTION FACTOR GATA 1; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BASE PAIRING; BINDING SITE; C3AR GENE; CELL LINE; COMPLEMENT SYSTEM; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA BINDING; DNA FOOTPRINTING; ENHANCER REGION; GEL MOBILITY SHIFT ASSAY; GENE; GENE CONTROL; GENE EXPRESSION REGULATION; GENE SEQUENCE; MACROPHAGE; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SEQUENCE ANALYSIS; TRANSCRIPTION INITIATION SITE;

EID: 23844553745     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.5.3123     Document Type: Article

References (58)

1. Volanakis, J. E. 2002. The role of complement in innate and adaptive immunity. Curr. Top. Microbiol. Immunol. 266: 41-56.
2. Wetsel, R. A. 1995. Structure, function and cellular expression of complement anaphylatoxin receptors. Curr. Opin. Immunol. 7: 48-53.
3. Nataf, S., S. W. Levison, and S. R. Barnum. 2001. Expression of the anaphylatoxin C5a receptor in the oligodendrocyte lineage. Brain Res. 894: 321-326.
4. Armstrong, R. C., L. Harvath, and M. E. Dubois-Dalcq. 1990. Type 1 astrocytes and oligodendrocyte-type 2 astrocyte glial progenitors migrate toward distinct molecules. J. Neurosci. Res. 27: 400-407.
5. Gasque, P., P. Chan, M. Fontaine, A. Ischenko, M. Lamacz, O. Gotze, and B. P. Morgan. 1995. Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J. Immunol. 155: 4882-4889.
6. Sayah, S., A. C. Jauneau, C. Patte, M. C. Tonon, H. Vaudry, and M. Fontaine. 2003. Two different transduction pathways are activated by C3a and C5a anaphylatoxins on astrocytes. Brain Res. Mol. Brain Res. 112: 53-60.
7. Mukherjee, P., and G. M. Pasinetti. 2000. The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease. J. Neuroimmunol. 105: 124-130.
8. O'Barr, S. A., J. Caguioa, D. Gruol, G. Perkins, J. A. Ember, T. Hugli, and N. R. Cooper. 2001. Neuronal expression of a functional receptor for the C5a complement activation fragment. J. Immunol. 166: 4154-4162.
9. Markiewski, M. M., D. Mastellos, R. Tudoran, R. A. DeAngelis, C. W. Strey, S. Franchini, R. A. Wetsel, A. Erdei, and J. D. Lambris. 2004. C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury. J. Immunol. 173: 747-754.
10. Strey, C. W., M. Markiewski, D. Mastellos, R. Tudoran, L. A. Spruce, L. E. Greenbaum, and J. D. Lambris. 2003. The proinfiammatory mediators C3a and C5a are essential for liver regeneration. J. Exp. Med. 198: 913-923.
11. Drouin, S. M., J. Kildsgaard, J. Haviland, J. Zabner, H. P. Jia, P. B. McCray, Jr., B. F. Tack, and R. A. Wetsel. 2001. Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J. Immunol. 166: 2025-2032.
12. Laudes, I. J., J. C. Chu, M. Huber-Lang, R. F. Guo, N. C. Riedemann, J. V. Sarma, F. Mahdi, H. S. Murphy, C. Speyer, K. T. Lu, et al. 2002. Expression and function of C5a receptor in mouse microvascular endothelial cells. J. Immunol. 169: 5962-5970.
13. Humbles, A. A., B. Lu, C. A. Nilsson, C. Lilly, E. Israel, Y. Fujiwara, N. P. Gerard, and C. Gerard. 2000. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 406: 998-1001.
14. Bautsch, W., H. G. Hoymann, Q. Zhang, I. Meier-Wiedenbach, U. Raschke, R. S. Ames, B. Sohns, N. Flemme, A. Meyer zu Vilsendorf, M. Grove, A. Klos, and J. Kohl. 2000. Cutting edge: guinea pigs with a natural C3a receptor defect exhibit decreased 27 bronchoconstriction in allergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma. J. Immunol. 165: 5401-5405.
15. Drouin, S. M., D. B. Corry, J. Kildsgaard, and R. A. Wetsel. 2001. Cutting edge: the absence of C3 demonstrates a role for complement in Th2 effector functions in a murine model of pulmonary allergy. J. Immunol. 167: 4141-4145.
16. Kawamoto, S., A. Yalcindag, D. Laouini, S. Brodeur, P. Bryce, B. Lu, A. A. Humbles, H. Oettgen, C. Gerard, and R. S. Geha. 2004. The anaphylatoxin C3a down-regulates the Th2 response to epicutaneously introduced antigen. J. Clin. Invest. 114: 399-407.
17. Drouin, S. M., D. B. Corry, T. J. Hollman, J. Kildsgaard, and R. A. Wetsel. 2002. Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J. Immunol. 169: 5926-5933.
18. Baelder, R., B. Fuchs, W. Bautsch, J. Zwirner, J. Kohl, H. G. Hoymann, T. Glaab, V. Erpenbeck, N. Krug, and A. Braun. 2005. Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J. Immunol. 174: 783-789.
19. Kildsgaard, J., T. J. Hollmann, K. W. Matthews, K. Bian, F. Murad, and R. A. Wetsel. 2000. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J. Immunol. 165: 5406-5409.
20. Boos, L., I. L. Campbell, R. Ames, R. A. Wetsel, and S. R. Barnum. 2004. Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis. J. Immunol. 173: 4708-4714.
21. Van Beek, J., M. Bernaudin, E. Petit, P. Gasque, A. Nouvelot, E. T. MacKenzie, and M. Fontaine. 2000. Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp. Neurol. 161: 373-382.
22. Barnum, S. R., R. S. Ames, P. R. Maycox, S. J. Hadingham, J. Meakin, D. Harrison, and A. A. Parsons. 2002. Expression of the complement C3a and C5a receptors after permanent focal ischemia: an alternative interpretation. Glia 38: 169-173.
23. van Beek, J., O. Nicole, C. Ali, A. Ischenko, E. T. MacKenzie, A. Buisson, and M. Fontaine. 2001. Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. Neuroreport 12: 289-293.
24. Gasque, P., S. K. Singhrao, J. W. Neal, P. Wang, S. Sayah, M. Fontaine, and B. P. Morgan. 1998. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J. Immunol. 160: 3543-3554.
25. Davoust, N., J. Jones, P. F. Stahel, R. S. Ames, and S. R. Barnum. 1999. Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells. Glia 26: 201-211.
26. Monsinjon, T., P. Gasque, P. Chan, A. Ischenko, J. J. Brady, and M. C. Fontaine. 2003. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J. 17: 1003-1014.
27. Wright, K. L., and J. P. Ting. 1992. In vivo footprint analysis of the HLA-DRA gene promoter: cell-specific interaction at the octamer site and up-regulation of X box binding by Interferon γ. Proc. Natl. Acad. Sci. USA 89: 7601-7605.
28. Roglic, A., E. R. Prossnitz, S. L. Cavanagh, Z. Pan, A. Zou, and R. D. Ye. 1996. cDNA cloning of a novel G protein-coupled receptor with a large extracellular loop structure. Biochim. Biophys. Acta 1305: 39-43.
29. Crass, T., U. Raffetseder, U. Martin, M. Grove, A. Klos, J. Kohl, and W. Bautsch. 1996. Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells. Eur. J. Immunol. 26: 1944-1950.
30. Ames, R. S., Y. Li, H. M. Sarau, P. Nuthulaganti, J. J. Foley, C. Ellis, Z. Zeng, K. Su, A. J. Jurewicz, R. P. Hertzberg, D. J. Bergsma, and C. Kumar. 1996. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J. Biol. Chem. 271: 20231-20234.
31. Tornetta, M. A., J. J. Foley, H. M. Sarau, and R. S. Ames. 1997. The mouse anaphylatoxin C3a receptor: molecular cloning, genomic organization, and functional expression. J. Immunol. 158: 5277-5282.
32. Hsu, M. H., J. A. Ember, M. Wang, E. R. Prossnitz, T. E. Hugli, and R. D. Ye. 1997. Cloning and functional characterization of the mouse C3a anaphylatoxin receptor gene. Immunogenetics 47: 64-72.
33. Hammond, M. P., and E. Birney. 2004. Genome information resources: developments at Ensembl. Trends Genet. 20: 268-272.
34. Smale, S. T. 1997. Transcription initiation from TATA-less promoters within eukaryotic protein-coding genes. Biochim. Biophys. Acta 1351: 73-88.
35. Gerard, N. P., L. Bao, H. Xiao-Ping, R. L. Eddy, Jr., T. B. Shows, and C. Gerard. 1993. Human chemotaxis receptor genes cluster at 19q13.3-13.4: characterization of the human C5a receptor gene. Biochemistry 32: 1243-1250.
36. Hu, H., B. K. Martin, J. J. Weis, and J. H. Weis. 1997. Expression of the murine CD21 gene is regulated by promoter and intronic sequences. J. Immunol. 158: 4758-4768.
37. Gentles, A. J., and S. Karlin. 1999. Why are human G-protein-coupled receptors predominantly intronless? Trends Genet. 15: 47-49.
38. Karin, M., Z. Liu, and E. Zandi. 1997. AP-1 function and regulation. Curr. Opin. Cell Biol. 9: 240-246.
39. Sharrocks, A. D. 2001. The ETS-domain transcription factor family. Nat. Rev. Mol. Cell Biol. 2: 827-837.
40. Martin, B. K., and J. H. Weis. 1993. Functional identification of transcription control sequences of the mouse Crry gene. J. Immunol. 151: 857-869.
41. Li, R., H. Pei, and D. K. Watson. 2000. Regulation of Ets function by protein-protein interactions. Oncogene 19: 6514-6523.
42. Shaulian, E., and M. Karin. 2002. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4: E131-E136.
43. Zabel, M. D., W. Wheeler, J. J. Weis, and J. H. Weis. 2002. Yin Yang 1, Oct1, and NFAT-4 form repeating, cyclosporin-sensitive regulatory modules within the murine CD21 intronic control region. J. Immunol. 168: 3341-3350.
44. Zabel, M. D., and J. H. Weis. 2001. Cell-specific regulation of the CD21 gene. Int. Immunopharmacol. 1: 483-493.
45. Makar, K. W., C. T. Pham, M. H. Dehoff, S. M. O'Connor, S. M. Jacobi, and V. M. Holers. 1998. An intronic silencer regulates B lymphocyte cell- and stage-specific expression of the human complement receptor type 2 (CR2, CD21) gene. J. Immunol. 160: 1268-1278.
46. Ryseck, R. P., and R. Bravo. 1991. c-JUN, JUN B, and JUN D differ in their binding affinities to AP-1 and CRE consensus sequences: effect of FOS proteins. Oncogene 6: 533-542.
47. Chiu, R., P. Angel, and M. Karin. 1989. Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun. Cell 59: 979-986.
48. Schutte, J., J. Viallet, M. Nau, S. Segal, J. Fedorko, and J. Minna. 1989. jun-B inhibits and c-fos stimulates the transforming and trans-activating activities of c-jun. Cell 59: 987-997.
49. Sigvardsson, M., D. R. Clark, D. Fitzsimmons, M. Doyle, P. Akerblad, T. Breslin, S. Bilke, R. Li, C. Yeamans, G. Zhang, and J. Hagman. 2002. Early B cell factor, E2A, and Pax-5 cooperate to activate the early B cell-specific mb-1 promoter. Mol. Cell. Biol. 22: 8539-8551.
50. Granger, S. W., and H. Fan. 1998. In vivo footprinting of the enhancer sequences in the upstream long terminal repeat of Moloney murine leukemia virus: differential binding of nuclear factors in different cell types. J. Virol. 72: 8961-8970.
51. Chen, H., D. Ray-Gallet, P. Zhang, C. J. Hetherington, D. A. Gonzalez, D. E. Zhang, F. Moreau-Gachelin, and D. G. Tenen. 1995. PU.1 (Spi-1) autoregulates its expression in myeloid cells. Oncogene 11: 1549-1560.
52. Pankov, R., N. Neznanov, A. Umezawa, and R. G. Oshima. 1994. AP-1, ETS, and transcriptional silencers regulate retinoic acid-dependent induction of keratin 18 in embryonic cells. Mol. Cell. Biol. 14: 7744-7757.
53. Ahne, B., and W. H. Stratling. 1994. Characterization of a myeloid-specific enhancer of the chicken lysozyme gene: major role for an Ets transcription factor-binding site. J. Biol. Chem. 269: 17794-17801.
54. Boehlk, S., S. Fessele, A. Mojaat, N. G. Miyamoto, T. Werner, E. L. Nelson, D. Schlondorff, and P. J. Nelson. 2000. ATF and Jun transcription factors, acting through an Ets/CRE promoter module, mediate lipopolysaccharide inducibility of the chemokine RANTES in monocytic Mono Mac 6 cells. Eur. J. Immunol. 30: 1102-1112.
55. Cirillo, G., L. Casalino, D. Vallone, A. Caracciolo, D. De Cesare, and P. Verde. 1999. Role of distinct mitogen-activated protein kinase pathways and cooperation between Ets-2, ATF-2, and Jun family members in human urokinase-type plasminogen activator gene induction by interleukin-1 and tetradecanoyl phorbol acetate. Mol. Cell. Biol. 19: 6240-6252.
56. Tower, G. B., C. I. Coon, K. Belguise, D. Chalbos, and C. E. Brinckerhoff. 2003. Fra-1 targets the AP-1 site/2G single nucleotide polymorphism (ETS site) in the MMP-1 promoter. Eur. J. Biochem. 270: 4216-4225.
57. El-Tanani, M., A. Platt-Higgins, P. S. Rudland, and F. C. Campbell. 2004. Ets gene PEA3 cooperates with β-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. J. Biol. Chem. 279: 20794-20806.
58. Gutman, A., and B. Wasylyk. 1990. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. EMBO J. 9: 2241-2246.